William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andy Hsieh has given his Buy rating due to a combination of factors that highlight the potential of Viking Therapeutics’ VK2735 in the obesity market. The initiation of the Phase III VANQUISH program, which includes trials for both individuals with and without type 2 diabetes, demonstrates a comprehensive approach to addressing obesity. The trials will assess the efficacy of VK2735 at various doses, which are strategically aligned to potentially offer better patient access compared to existing treatments like Zepbound.
Furthermore, the dosing flexibility and the exploration of both subcutaneous and oral formulations of VK2735 could enhance its appeal in the market. The potential for improved reimbursement dynamics and increased utility through direct-to-consumer channels also contribute to the positive outlook. These factors combined suggest that VK2735 could disrupt the current market and provide significant value, justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $102.00 price target.